{
    "clinical_study": {
        "@rank": "122545", 
        "arm_group": [
            {
                "arm_group_label": "Fleet enema", 
                "arm_group_type": "Active Comparator", 
                "description": "This group will receive Fleet enema as their treatment"
            }, 
            {
                "arm_group_label": "TF037", 
                "arm_group_type": "Experimental", 
                "description": "This group will receive TF037 as their treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to assess the difference between the performance of a new enema\n      (TF037) against Fleet enema in distal bowel cleansing."
        }, 
        "brief_title": "A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet Enema", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Colonoscopy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or female subjects [as determined by medical history, physical\n             examination, laboratory test values, vital signs and 12-lead electrocardiograms\n             (ECGs) at screening] aged 18 to 60 years.\n\n          -  Non-smokers from 3 months before enema administration and for the duration of the\n             clinical investigation.\n\n          -  Body mass index (BMI) \u2265 18 and \u2264 35 kg/m2.\n\n          -  Must voluntarily provide written informed consent to participate in the clinical\n             investigation.\n\n          -  Must understand the purposes and risks of the clinical investigation and agree to\n             follow the restrictions and schedule of procedures as defined in the clinical\n             investigation plan, and as confirmed during the informed consent process.\n\n          -  Female subjects must be postmenopausal (for at least one year and confirmed by a\n             serum follicle stimulating hormone (FSH) test at screening), surgically sterile,\n             practising true sexual abstinence or must use an effective method of contraception.\n\n          -  Female subjects of child-bearing potential must have a negative serum pregnancy test\n             at screening and a negative urine pregnancy test at check-in of each period.\n\n          -  The subject's primary care physician must confirm that there is nothing in their\n             medical history that would preclude their enrolment into this clinical investigation.\n\n          -  Must be willing to consent to have data entered into The Over Volunteering Prevention\n             System (TOPS).\n\n        Exclusion Criteria:\n\n          -  Subjects with a history or presence of significant cardiovascular disease, pulmonary,\n             hepatic, gallbladder or biliary tract, renal, haematologic, gastrointestinal,\n             endocrine, immunologic, dermatologic, neurologic or psychiatric disease.\n\n          -  Subjects with a history or presence of organic or functional gastrointestinal\n             conditions (e.g. chronic constipation, irritable bowel syndrome, inflammatory bowel\n             disease).\n\n          -  Subjects with a clinically relevant history or presence of abnormal gastrointestinal\n             motility.\n\n          -  Subjects with a significant history of hereditary bowel disorders.\n\n          -  Subjects with abnormal findings on the digital rectal examination performed at\n             screening.\n\n          -  Use of laxatives or motility altering drugs in the 3 months preceding enema\n             administration.\n\n          -  Use of any prescription or over-the-counter medication (including vitamins, herbal\n             and mineral supplements) within 14 days prior to enema administration (or within 5\n             half lives if longer), with the exception of Investigator-approved hormonal\n             contraceptives, hormone replacement therapy (HRT) and occasional paracetamol, aspirin\n             or ibuprofen.\n\n          -  Participation in a clinical drug study during the 30 days preceding enema\n             administration in this clinical investigation.\n\n          -  Donation of blood or blood products within 30 days prior to enema administration or\n             during the clinical investigation, except as required for this clinical investigation\n\n          -  Pregnant or lactating females.\n\n          -  Any clinically significant illness within 28 days prior to enema administration.\n\n          -  History or presence of any significant drug allergy, or a known allergy or\n             contraindication to trisodium citrate, Fleet\u00ae enema or midazolam.\n\n          -  Laboratory values at screening which are deemed to be clinically significant, unless\n             agreed in advance by the Sponsor's Medical Representative and Principal Investigator.\n\n          -  Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.\n\n          -  Current or history of drug or alcohol abuse within the 12 months prior to enema\n             administration, or a positive drugs of abuse test at screening or check-in.\n\n          -  Consumption of alcoholic beverages within 24 hours of check-inor during confinement.\n\n          -  Subjects who, in the opinion of the Investigator, are unsuitable for participation in\n             the clinical investigation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715272", 
            "org_study_id": "NER1008-01/2012 (DBC)"
        }, 
        "intervention": [
            {
                "arm_group_label": "TF037", 
                "intervention_name": "TF037", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Fleet enema", 
                "intervention_name": "Fleet enema", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sodium phosphate"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Belfast", 
                        "country": "United Kingdom", 
                        "state": "Northern Ireland", 
                        "zip": "BT2 7BA"
                    }, 
                    "name": "BioKinetic Europe Ltd"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belfast", 
                        "country": "United Kingdom"
                    }, 
                    "name": "BioKinetic Europe Ltd"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet Enema", 
        "overall_official": {
            "affiliation": "BioKinetic Europe Ltd.", 
            "last_name": "Ronnie Beboso, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Performance of TF037 in distal bowel cleansing compared to Fleet enema using the Harefield Cleansing scale", 
            "safety_issue": "No", 
            "time_frame": "Between 1 to 3 hours following enema administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715272"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare the stool output (as measured as stool weight) during the 1 hour period following enema administration for TF037 and Fleet enema", 
                "measure": "Stool output as measured by stool weight", 
                "safety_issue": "No", 
                "time_frame": "up to 1 hour following enema administration"
            }, 
            {
                "description": "To assess the safety (including effects on water homeostasis) and tolerability of this medical device in its intended purpose", 
                "measure": "Safety and tolerability as assessed by use of a Visual Analogue scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "5 and 30 minutes following enema administration"
            }, 
            {
                "description": "To assess kinetics of bowel movements in relation to stool output over time", 
                "measure": "Stool output over time", 
                "safety_issue": "No", 
                "time_frame": "1 hour following enema administration"
            }
        ], 
        "source": "Norgine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Norgine", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}